GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » PB Ratio

Catalyst Pharmaceuticals (FRA:CN2) PB Ratio : 3.42 (As of May. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Catalyst Pharmaceuticals's share price is €14.96. Catalyst Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €4.38. Hence, Catalyst Pharmaceuticals's PB Ratio of today is 3.42.

The historical rank and industry rank for Catalyst Pharmaceuticals's PB Ratio or its related term are showing as below:

FRA:CN2' s PB Ratio Range Over the Past 10 Years
Min: 1.97   Med: 4.02   Max: 12.17
Current: 3.35

During the past 13 years, Catalyst Pharmaceuticals's highest PB Ratio was 12.17. The lowest was 1.97. And the median was 4.02.

FRA:CN2's PB Ratio is ranked worse than
62.17% of 1311 companies
in the Biotechnology industry
Industry Median: 2.5 vs FRA:CN2: 3.35

During the past 12 months, Catalyst Pharmaceuticals's average Book Value Per Share Growth Rate was 51.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 30.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 48.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 24.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Catalyst Pharmaceuticals was 337.00% per year. The lowest was -41.30% per year. And the median was 22.60% per year.

Back to Basics: PB Ratio


Catalyst Pharmaceuticals PB Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals PB Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.35 2.02 3.53 6.28 4.64

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.07 3.77 3.63 4.64 3.41

Competitive Comparison of Catalyst Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's PB Ratio falls into.



Catalyst Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Catalyst Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=14.96/4.376
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Catalyst Pharmaceuticals  (FRA:CN2) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Catalyst Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (FRA:CN2) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines